In conclusion, this analysis confirms the durable and robust antitumor activity and safety of dabrafenib combined with trametinib in Chinese patients with BRAF V600 mutation-positive melanoma, including acral melanoma patients. This evidence concerns the gene BRAF and acral lentiginous melanoma.